Claims for Patent: 6,346,517

Summary for Patent: 6,346,517

Title:	Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
Abstract:	This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.
Inventor(s):	Wong; Pancras C. (Wilmington, DE), Mousa; Shaker A. (Lincoln University, PA)
Assignee:	Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:	09/523,395
Patent Claims:	1. A method for treating a condition selected from the group: acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombic occlusion and reclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke comprising administration of a sub-therapeutic dose of a low molecular weight heparin and a sub-therapeutic dose of a platelet GPIIb/IIIa antagonist to a mammal in need of such treatment. 2. A method according to claim 1, wherein the platelet GPIIb/IIIa antagonist is roxifiban. 3. A method according to claim 1, wherein the low molecular weight heparin is tinzaparin. 4. A method according to claim 1, wherein the administration is subcutaneous. 5. A pharmaceutical composition comprising a platelet GPIIb/IIIa antagonist and a low molecular weight heparin and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition according to claim 5, wherein the platelet GPIIb/IIIa antagonist is roxifiban. 7. A pharmaceutical composition according to claim 5, wherein the low molecular weight heparin is tinzaparin. 8. A kit comprising a platelet GPIIb/IIIa antagonist and a low molecular weight heparin for subcutaneous injection. 9. A method of treating thrombosis in a mammal comprising administering to said mammal a combination of: (i) a subtherapeutic dose of GPIIb/IIIa antagonist selected from the group consisting of abciximab, eptifibatide, tirofiban, lamifiban, lefradafiban, sibrafiban, orbofiban, xemilofiban, a compound of the formula (A): ##STR12## and a compound of the formula (B): ##STR13## and (ii) aspirin or (iii) a low molecular weight heparin selected from the group consisting of tinzaparin, certoparin, parnaparin, nadroparin, ardeparin, enoxaparin, reviparin, reviparin and dalteparin. 10. The method of claim 9 wherein the combination of (i) and (ii) or (iii) provides a synergistic effect. 11. The method of claim 9, wherein the combination administered is a combination of the GPIIb/IIIa antagonist and a low molecular weight heparin. 12. The method of claim 11, wherein the GPIIb/IIIa antagonist is administered in a subtherapeutic amount. 13. The method of claim 11, wherein the GPIIb/IIIa antagonist is compound A or compound B. 14. The method of claim 11, wherein the low molecular weight heparin is dalteparin (fragmin). 15. The method of claim 11, wherein the GPIIb/IIIa antagonist is compound A or compound B and the low molecular weight heparin is dalteparin (fragmin). 16. A method of treating thrombosis in a mammal comprising administering to said mammal (i) tissue plasminogen activator and (ii) a compound of the formula: ##STR14##

Details for Patent 6,346,517

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2019-03-11